Building a new model of sustainable chemistry. Meeting with Investors at VFB-Happening 2014 Karim Hajjar CFO
|
|
- Thomas May
- 5 years ago
- Views:
Transcription
1 Building a new model of sustainable chemistry Meeting with Investors at VFB-Happening 2014 Karim Hajjar CFO
2 Solvay at a glance Acceleration of Solvay s transformation Delivery in a challenging economic context Strong fundamentals to create value 2 Forenote All references to 2012 Income Statement data are restated for: the Group s new business organization effective as from January 1, 2013; the application of IAS 19 revised; the Group s European Chlorovinyls activities planned to be contributed to the JV with Ineos. The European Chlorovinyls business activities are reflected as Assets Held For Sale on the balance sheet (in one single line) and as discontinued operations in the Income Statement as required by IFRS. As from December 31, 2013, Benvic (the PVC compounding business) is reflected in the Balance Sheet as "Assets Held for Sale", but as continued operations in the Income Statement. Chemlogics is consolidated in the financial statements from November 1, Solvay is presenting Adjusted Income Statement performance indicators that exclude non-cash Purchase Price Allocation (PPA) accounting impacts related to the Rhodia acquisition. Furthermore, all figures are historical figures before restatement for IFRS 11 applied by Solvay as from Jan 1st 2014.
3 Solvay at a glance Acceleration of Solvay s transformation Delivery in a challenging economic context Strong fundamentals to create value 3
4 Solvay, a major global chemical player 9.9 bn Net sales 1.7 bn REBITDA Based on strengths Well-balanced geographical spread and end-user markets 117 Industrial sites 15 Major R&I centers 16.7% REBITDA margin Leading player in 90% of our businesses 29,400 Employees (EFTEs) 378 m Adjusted Net Income, Group share Strong R&I portfolio 56 Country presence All figures excluding discontinued operations, except for employees Building a new model of sustainable chemistry 4
5 Well-balanced geographical spread and end-user markets Balanced geographic exposure* Exposure to high growth end-markets* 5 North America 25% Latin America 11% Europe 33% * Figures represent % of 2013 net sales (pro-forma Chemlogics) Asia Pacific & RoW 31% Aeronautics & Automotive 17% Consumer Goods & Healthcare 25% Agro Food 12% Energy & Environment 11% Building & Construction 10% Electrical & Electronics 6% Industrial Applications 19%
6 Building a new model of sustainable chemistry Our commitments Planet Customers Reach excellence in safety & health Deploy unmatched sustainable portfolio management Reduce our impact on environment by 2020 Investors Suppliers Energy consumption Greenhouse gas emissions Groundwater consumption Air emission Water emissions Sustainable water management Communities Develop rich & balanced social dialogue Employees 6
7 Solvay at a glance Acceleration of Solvay s transformation Delivery in a challenging economic context Strong fundamentals to create value 7
8 Converting vision into value Our vision Our 2016 ambition Build a strong global leader in the chemical industry Be a model of sustainable chemistry Become a high growth, less capital intensive & high return Group REBITDA to reach bn REBITDA margin to reach 18% CFROI* to increase by >100 bp vs /3 rd of businesses in value-creation zone Being a model of sustainability Reducing our impact on environment * CFROI = REBITDA Rec. Capex Tax Gross assets + Working Capital 8
9 A clearly defined strategy Our strategy Business profile enhanced Reinforcing business profile through strategic portfolio changes Striving for excellence across businesses Innovating to create sustainable solutions Solvay s ability to extract value ENHANCE Solvay YE 2012 RESTORE GROW Solvay YE 2013 Chemlogics Chemical industry Transforming company culture with a focus on performance EXIT Value creation potential of industry segment Solvay businesses 9
10 Strong innovation portfolio aligned with global megatrends 2013 Climate change 15 Resource scarcity Advanced materials Major sites worldwide 1,950 Advanced formulations R&I staff Health & well being Renewable chemistry R&I efforts 22% Next bn consumers Organic electronics Q4 & FY 2013 results 26/02/2014 New sales ratio Sustainable energy Ecoprocesses m 251 Patents filed
11 REBITDA growth supported by strong operational levers REBITDA In m Inflation Operational excellence > 10% CAGR Organic growth Innovation Portfolio 2,300-2, ,663 Chemlogics (10 months) (260) 300 Industrial excellence Purchasing, supply & other efficiencies 280 New production capacities Commercial excellence Innovative products Innovation excellence Example: 2013* 2016 * Chemlogics consolidated for 2 months 11
12 A strong team with a proven track record Executive Committee as of Jan 1st, 2014 Jean-Pierre Clamadieu Karim Hajjar Vincent De Cuyper Pascal Juery Roger Kearns Jacques van Rijckevorsel CEO CFO Advanced Formulations Advanced Materials Performance Chemicals Functional Polymers Solvay Energy Services E. Butstraen Novecare A. Di Donfrancesco Specialty Polymers C. Clemente Soda Ash M. Laudenbach Polyamide & Intermediates P. Rosier Solvay Energy Services V. Kamel Coatis T. Benner Silica G. Crauser Peroxides F. Hincker Engineering Plastics D. Rage Aroma Performance H. Du Rare Earth Systems O. Ferrary Acetow F. Ferraroli Fibras B. Wilkes J. Harton Special Chemicals Eco Services B. Van der Wielen Emerging Biochemicals 12
13 A performance culture to move from good to great Internal campaign Customer-centric, empowered, entrepreneurial, result-oriented Employer branding campaign 13
14 Solvay at a glance Acceleration of Solvay s transformation Delivery in a challenging economic context Strong fundamentals to create value 14
15 FY 2013 results: demonstrating our resilience in a difficult environment Net Sales 9.9 bn (5)% yoy Forex headwinds Raw materials deflation Volume decrease primarily related to CER phase-out REBITDA 1,663 m (12)% yoy Stable allowing for exceptionals & Chemlogics CER phase-out and guar effect exceptionals Pricing power preserved Excellence programs delivering Net Income 378 m Adjusted, Group Share Significant non-recurring costs (239) m (e.g. restructuring for integration and excellence) FCF 524 m Net Debt 1,102 M Strong Free Cash Flow Stable Net Debt Hybrid bonds of 1.2 bn classified in Equity Stable dividend proposed at 3.20 gross / share 15
16 Stable underlying REBITDA allowing for exceptionals (carbon credits and guar) In m 1, Pricing power +3 M 1 % Structure Carbon credits -7 % Volumes & mix Guar -11 % Selling price 11 % Raw materials & energy costs -2 % Fixed costs ~-100 Guar -5% Result of Hichem JV 9 1% Others Other JV results ~ 18 Conversion -36 Other 27 1, % Margin Margin 18.0% 16.7% 16
17 Stable total dividend proposed Solvay s gross dividend in /share 2013 CAGR >5% 3.20 / share (gross) dividend proposed 1.33 interim dividend paid in January balance to be paid in May Over more than 30 years 40% average pay out Committed to stable / growing dividend 17
18 Solvay share price performance compared to indexes since January 2012 Until April 22, Solvay +77% BEL 20 CAC January 2012 January 2013 April
19 Solvay at a glance Acceleration of Solvay s transformation Delivery in a challenging economic context Strong fundamentals to create value 19
20 Executing a clear value creation strategy Progress on many fronts Poised for growth On track towards 2016 targets Towards a higher growth, improved cash generation & enhanced returns Chemical Group Targeting Sustainable Value Growth 20
21
Solvay expands its specialty polymers offerings with Ryton PPS acquisition
Solvay expands its specialty polymers offerings with Ryton PPS acquisition Sustained strategic portfolio realignment With Ryton PPS* acquisition, Solvay further strengthens unmatched leadership in Specialty
More informationTable of Contents. 1. About Solvay Solvay at a Glance Group Portfolio Transforming Solvay Solvay s Portfolio Upgrade 7
Solvay Media Kit Table of Contents 1. About Solvay 3 1.1. Solvay at a Glance 4 1.2. Group Portfolio 5 2. Transforming Solvay 6 2.1. Solvay s Portfolio Upgrade 7 3. Organizing for the Future 9 3.1. Why
More informationSolvay India April 2017
Solvay India April 2017 Solvay in India Ahmedabad, Jodhpur, Bhiwani Hichem (JV) (GUAR) Solvay Specialty Polymer India & Panoli Solvay Engineering Plastics (PEEK, PAEK Polysulfones, Polyamide compounds)
More informationLaunch of a new binders : Leveraging innovation to an economic advantage.
Launch of a new binders : Leveraging innovation to an economic advantage. Maximizing customers benefit by reducing cost of change Roberta Colombo & Thierry Baert The cost of innovation for materials. The
More informationBuilding a model of sustainable chemistry
Building a model of sustainable chemistry March, 2015 Focused on bringing worldclass & sustainable Chemistry Solvay in India 264 million net sales ( Excl. JV but includes ~64 meuro export) 778 Employees
More informationNutrition Chris Goppelsroeder President & CEO DSM Nutritional Products ROYAL DSM HEALTH NUTRITION MATERIALS
Nutrition Chris Goppelsroeder President & CEO DSM Nutritional Products ROYAL DSM HEALTH NUTRITION MATERIALS Safe harbor statement This presentation may contain forward-looking statements with respect to
More informationSpiros Nomikos Chief Executive Officer Solvay Sodi Bulgaria
Spiros Nomikos Chief Executive Officer Solvay Sodi Bulgaria FINANCIAL TIMES INVESTING IN BULGARIA CONFERENCE Investment Opportunities in Bulgaria The Case of Solvay Sodi Spiros Nomikos CEO of Solvay Sodi
More informationNomura Healthcare Conference
Nomura Healthcare Conference Sebastien Martel Head of Investor Relations London, July 1st, 2011 Forward Looking Statements 2 This presentation contains forward-looking statements as defined in the Private
More informationCPH Chemie + Papier Holding AG. Investor Day. Perlen, 13 th September 2018
CPH Chemie + Papier Holding AG Investor Day Perlen, 13 th September 2018 Agenda 2.00 pm Welcome 2.05 pm Presentation Course of Business 2018 2.50 pm Break 3.00 pm Presentation Perlen Packaging 3.30 pm
More informationValue creation through profitable growth Handelsbanken Nordic Large Cap Seminar, Stockholm 2016 Anders Lonning-Skovgaard, CFO
Value creation through profitable growth Handelsbanken Nordic Large Cap Seminar, Stockholm 2016 Anders Lonning-Skovgaard, CFO Coloplast has four business areas all with global sales presence Group revenue
More informationFor personal use only
Cochlear Limited Results for the half year ended 31 December 2011 (H1 F12) Chris Roberts, CEO Neville Mitchell, CFO Cochlear Overview Cochlear Limited (ASX:COH): global leader in implantable devices for
More informationADM to Acquire Neovia and Probiotics International Limited. July 2, 2018
ADM to Acquire Neovia and Probiotics International Limited July 2, 2018 Safe Harbor Statement 2 Some of our comments constitute forward-looking statements that reflect management s current views and estimates
More informationDIEBOLD NIXDORF AG AT GERMANY EQUITY FORUM
November 28, 2017 DIEBOLD NIXDORF AG AT GERMANY EQUITY FORUM Dr. Jürgen Wunram Agenda Diebold Nixdorf AG History and shareholder structure Market trends, strategy and progress of integration Diebold Nixdorf
More informationGBU data & processes
GBU data & processes Consumer Chemicals Novecare at a Glance Growth on inspired products Net sales 2013e 1.6 bn 11 prod. Sites (+1 under construction) 12 R&I centers 5 prod. Sites (+1 under construction)
More informationBALCHEM CORPORATION. Q Investor Relations Presentation
BALCHEM CORPORATION Q4 2017 Investor Relations Presentation Balchem Corporation Balchem develops, manufactures, and markets specialty ingredients that improve and enhance the health and well being of life
More informationDriving Profitable Growth
Driving Profitable Growth through science-based, sustainable solutions Feike Sijbesma, CEO Royal DSM CONSUMER ANALYST GROUP EUROPE, London 22 March 2016 ROYAL DSM HEALTH NUTRITION MATERIALS Safe harbor
More informationConsolidated: Financial Summary
FY2010 First Quarter Financial Results SUZUKI MOTOR CORPORATION 3 August 2010 Consolidated: Financial Summary Page2 FY2010 1Q FY2009 1Q (2010/4-6) (2009/4-6) Change Net sales 656.3 577.1 +79.2 +13.7% Operating
More informationASKING MORE 2015 COMPLEMENTARY ANNUAL REPORT - SUSTAINABLE DEVELOPMENT INFORMATIONS
ASKING MORE 2015 COMPLEMENTARY ANNUAL REPORT - SUSTAINABLE DEVELOPMENT INFORMATIONS INTRODUCTION SUSTAINABLE VALUE CREATION Our strategy is a virtuous circle in which positive actions interact to create
More information1Q2005. Hera Group presentation
1Q2005 Hera Group presentation 1 Y2005 has been characterized by a stream of achievements: Corporate Governance A new BoD was appointed in April. Further penetration of the Hera Gas market: 1,500 new clients
More informationJanuary 30, 2018 Dow Wilson President and Chief Executive Officer
Acquisition of SIRTeX January 30, 2018 Dow Wilson President and Chief Executive Officer This presentation is intended exclusively for investors. It is not intended for use in Sales or Marketing. Forward-Looking
More informationWELCOME TO ACTELION S AGM 2015
WELCOME TO ACTELION S AGM 2015 08 May 2015 Copyright 2015 Actelion Pharmaceuticals Ltd ACTELION S ANNUAL GENERAL MEETING 2015 MEETING STRUCTURE Opening Remarks Business Review 2014 Agenda & Proposals Jean-Pierre
More informationSolvay in India January, 2014
Solvay in India January, 2014 SOLVAY in India, Innovation and Operational excellence Jodhpur Hichem (JV) Ahmedabad Hichem (JV) Bhiwani Hichem (JV) Delhi Hichem (JV) Solvay R&D center Vadodara Panoli Solvay
More informationValue creation through profitable growth Danske Bank Winter Seminar 2017, Copenhagen Lars Rasmussen, President & CEO
Value creation through profitable growth Danske Bank Winter Seminar 2017, Copenhagen Lars Rasmussen, President & CEO Forward-looking statements The forward-looking statements contained in this presentation,
More informationKey figures (consolidated)
Nestlé Group 2013 Key figures (consolidated) In millions of CHF (except for data per share) 2013 Results Sales 92158 Trading operating profit 14047 as % of sales 15.2% Profit for the year attributable
More informationForward Looking Information
Vital Signs, Inc. Forward Looking Information Except for historical information discussed, the statements made today are forward-looking statements that involve risks and uncertainties. Investors are cautioned
More information1Q Fornebu, April 29, 2015 Luis Araujo and Svein Stoknes
1Q 2015 Fornebu, April 29, 2015 Luis Araujo and Svein Stoknes Forward-Looking Statements and Copyright This Presentation includes and is based, inter alia, on forward-looking information and statements
More informationOpening New Frontiers
Opening New Frontiers Roadshow presentation 2Q11 results 1 2 AGENDA Solvay, an industrial group active in Chemistry Friendly offer on Rhodia 2Q11 results 3 SOLVAY GROUP SOLVAY at a glance SOLVAY AN INDUSTRIAL
More informationThird-quarter results 2013
Third-quarter results 213 Fornebu, 6 November 213 Øyvind Eriksen and Leif Borge Agenda 213 Introduction Øyvind Eriksen Executive chairman Financials Leif Borge President & CFO Q&A Q&A session Øyvind Eriksen
More informationKAPITALMARKNADSDAG 20 SEPTEMBER Thomas Axelsson, CEO
KAPITALMARKNADSDAG 20 SEPTEMBER 2016 Thomas Axelsson, CEO 1 AGENDA 16.10-16.30 VD har ordet Thomas Axelsson, CEO 16.30-16.50 Clinical relevance of time-lapse Dr. Niels B. Ramsing, Business Unit Time-lapse,
More informationWelcome to the Full -Year Results Press Conference
Welcome to the Full -Year Results Press Conference Disclamer This presentation contains forward looking statements which reflect Management s current views and estimates. The forward looking statements
More informationFor personal use only
HY18 Result Presentation 13 February 2018 Dig Howitt Brent Cubis CEO & President CFO HY18 Result highlights Strong momentum across developed markets continues Developed market unit growth up 12% Strengthening
More informationColoplast A/S. Investor presentation 1H 2005/06
Coloplast A/S Investor presentation 1H 2005/06 2 Coloplast Coloplast products and services help patients achieve greater independence from medical challenges in 4 areas: Ostomy care, continence care, wound
More informationMINUTES OF THE ANNUAL SOLVAY S.A. SHAREHOLDERS MEETING On Tuesday, May 10, 2016 at 10:30 a.m.
MINUTES OF THE ANNUAL SOLVAY S.A. SHAREHOLDERS MEETING On Tuesday, May 10, 2016 at 10:30 a.m. The shareholders of the company Solvay S.A. with its corporate offices in Brussels, rue de Ransbeek, no. 310,
More informationBANK HANDLOWY W WARSZAWIE S.A. 1Q 2009 consolidated financial results -1-
BANK HANDLOWY W WARSZAWIE S.A. 1Q 29 consolidated financial results -1- Macroeconomic situation in 1Q 29 Deep drop in industrial output in January and February, albeit business confidence indicators suggest
More informationSüdzucker Group Capital market forum Rhine Neckar
Südzucker Group Capital market forum Rhine Neckar Mannheim, 7 November 2017 Thomas Kölbl (CFO) Südzucker Group, page 1 Südzucker Group at a glance Global operating German food group with long-standing
More informationHuman Nutrition Jeremy Xu President Human Nutritional & Health ROYAL DSM HEALTH NUTRITION MATERIALS
Human Nutrition Jeremy Xu President Human Nutritional & Health ROYAL DSM HEALTH NUTRITION MATERIALS Safe harbor statement This presentation may contain forward-looking statements with respect to DSM s
More informationJP Morgan 2011 Healthcare Conference. David Redfern, Chief Strategy Officer 12 January 2011
JP Morgan 2011 Healthcare Conference David Redfern, Chief Strategy Officer 12 January 2011 GSK performance through patent cliff + Avandia GSK patent cliff + Avandia 2006-2009 US turnover for se elected
More informationFY2009 First Quarter Financial Results. SUZUKI MOTOR CORPORATION August 3, 2009
FY2009 First Quarter Financial Results SUZUKI MOTOR CORPORATION August 3, 2009 Consolidated: Financial Summary Page 2 FY2009 1Q FY2008 4Q 09/4-6 09/1-3 Change FY2008 1Q 08/4-6 Change (Billion Yen) (A)
More informationThe acquisition of Fortitech
The acquisition of Fortitech Accelerating DSM s strategy to become a full solutions provider in food ingredient blends Investor Relations 8 November 2012 Overview Fortitech at a glance Acquisition rationale
More informationConsumer Wellness in India Growth Ahead
1 Consumer Wellness in India Growth Ahead Indian Health & Wellness industry Valued at over INR 590 bn, growing at CAGR of 18% - 20% p.a. Growth expected to continue. Industry growth being driven by: Increasing
More informationST. JUDE MEDICAL / THORATEC TRANSACTION HIGHLIGHTS July 22, 2015
ST. JUDE MEDICAL / THORATEC TRANSACTION HIGHLIGHTS July 22, 2015 1 FORWARD LOOKING STATEMENT This presentation contains forward-looking statements within the meaning of the Private Securities Litigation
More informationVision. Mission. Hopelink s Values. Introduction. A community free of poverty
Vision A community free of poverty Mission Hopelink s mission is to promote self-sufficiency for all members of our community; we help people make lasting change. Hopelink s Values Growth and Human Potential
More informationA GLOBAL LEADER IN PERSONALIZED NUTRITION
A GLOBAL LEADER IN PERSONALIZED NUTRITION Forward Looking Statements Management will make forward-looking statements during this presentation. Actual results could differ from those projected in such forward-looking
More informationELICA 2012 Q3 RESULTS. November 14,
ELICA ELICA 1 Q3 12 Highligths Negative market demand, showing better trend compared to previous quarters Group sales over performing in all major markets Cost reduction efforts and continued product innovation
More informationSummary of Results for the First Half of FY2015/3
Summary of Results for the First Half of FY2015/3 November 10, 2014 Tokyu Corporation (9005) http://www.tokyu.co.jp/ Contents Ⅰ.Executive Summary 2 Ⅱ.Conditions in Each Business 5 Ⅲ.Details of Financial
More informationForward-Looking Statements
Investor Presentation May 2012 Forward-Looking Statements Statements contained herein that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933, as amended.
More informationA world leader in allergy immunotherapy
A world leader in allergy immunotherapy Investor Relations presentation June 2017 1 I Investor Relations presentation I June 2017 ALK: Towards redefining treatment of severe allergies The commercial leader
More informationASX Investor Presentation
ASX Investor Presentation Sydney, Australia Dr Peter Neustadt Executive Chairman and CEO November 2014 Copyright and registered trademark notice ASX Investor Presentation Page 0 Who we are SomnoMed Limited
More informationResMed Inc. 36 th Annual J.P. Morgan Healthcare Conference
ResMed Inc. 36 th Annual J.P. Morgan Healthcare Conference Mick Farrell CEO January 8, 2018 Safe Harbor Statement Statements contained in this presentation that are not historical facts are forwardlooking
More informationWalgreen Co. Reports Second Quarter 2010 Earnings Per Diluted Share of 68 Cents; Results Include 2 Cents Per Diluted Share of Restructuring Costs
Walgreen Co. Reports Second Quarter 2010 Earnings Per Diluted Share of 68 Cents; Results Include 2 Cents Per Diluted Share of Restructuring Costs Second quarter sales up 3.1 percent to record $17.0 billion
More informationLeading Intimate Healthcare. Investor presentation Q1 2007/08
Leading Intimate Healthcare Investor presentation Q1 2007/08 1 2 Agenda Introduction to Coloplast Q1 2007/08 in headlines Outlook for 2007/08 Strategic targets Leading intimate healthcare Appendices Q1
More informationFinancial Presentation
Financial Presentation Certain of the statements that will be made during this meeting, as well as statements contained in our 2006 Annual Report to Shareholders and Annual Report on Form 10-K filed with
More informationLetter to Shareholders SEMI-ANNUAL REPORT 2008
Letter to Shareholders SEMI-ANNUAL REPORT 2008 Dear Shareholder You have in your hand the first shareholder letter issued by Nobel Biocare. Thanks to the conversion of Nobel Biocare s bearer shares into
More informationLeading Intimate Healthcare
21 May 2008 1 Leading Intimate Healthcare Investor presentation H1 2007/08 2 Agenda Introduction to Coloplast First 6 months 2007/08 in headlines Outlook for 2007/08 Strategic targets Leading intimate
More informationEnel Américas 1Q 2018 results
Enel Américas 1Q 2018 results 1Q 2018 results Highlights of the period EBITDA of 820 musd, an increase of 26% vs 1Q 2017 Generation EBITDA increased by 17% due to better prices in Argentina and consolidation
More information2014 Full Year Results Presentation. Year ended 31 March 2014
2014 Full Year Results Presentation Year ended 31 March 2014 26-30 May 2014 1 Full year result highlights 12 months to 31 March 2014 NZ$M PCP CC 1 Record net profit after tax 97.1 +26% +46% Record operating
More informationResults Presentation 2Q FY March Win-Partners Co., Ltd. (3183)
Results Presentation 2Q FY March 2018 Win-Partners Co., Ltd. (3183) 2Q results ending September 2017 Consolidated results summary ( mil)2q to Sep 2016 Sep 2017 YoY OE Sales 27,713 29,753 +7.4% 29,500 Operating
More informationPassion for progress, care for people
Passion for progress, care for people SPIL Analyst Meeting 25 th April, 2008 DISCLAIMER ACTUAL RESULTS / OUTCOMES MAY BE DIFFERENT FROM ANY FORWARD LOOKING STATEMENTS / VIEWS / ESTIMATES EXPRESSED HEREIN.
More informationCowen Healthcare Conference
Cowen Healthcare Conference Shire plc March 9, 2010 Michael Cola President, Specialty Pharmaceuticals Our purpose We enable people with life-altering conditions to lead better lives 1 THE SAFE HARBOR STATEMENT
More informationVery good Q3 contribution from Vegetable Juices Inc.
2014 nine-month sales (1 st January to 30 September 2014) Very good Q3 contribution from Vegetable Juices Inc. Worldwide economic environment still adverse Sustained growth by Food & Beverage Press release
More informationFIRSTQUARTER2018 RESULTSPRESENTATION
FIRSTQUARTER2018 RESULTSPRESENTATION May 14 th 2018 Juan Lladó CEO 1 DISCLAIMER This document has been prepared by Técnicas Reunidas S.A. (the Company) solely for use at presentations held in connection
More informationResults Presentation 2Q FY March Win-Partners Co., Ltd. (3183)
Results Presentation 2Q FY March 2019 Win-Partners Co., Ltd. (3183) 2Q results ending September 2019 3 Consolidated results summary ( mil)2q to Sep 2017 Sep 2018 YoY OE Sales 29,753 31,863 +7.1% 31,700
More informationWaste Heat Recovery Opportunities in Cement Market and Supplier Analysis. Intercem Conference. Nairobi, Kenya June 16-18, 2014
Waste Heat Recovery Opportunities in Cement Market and Supplier Analysis Intercem Conference Nairobi, Kenya June 16-18, 2014 Waste Heat Recovery in Cement Cement production more than doubled b/w 2002 and
More informationWelcome to LG Electronics
Welcome to LG Electronics April 21, 2004 As a note, this presentation has been prepared based on internal audited figures and final figures may change due to the results of independent auditors review.
More informationInvestor Day LA&C Region Lausanne, September 29, Jeanne Pollès President, Latin America & Canada Region
Investor Day LA&C Region Lausanne, September 29, 2016 Jeanne Pollès President, Latin America & Canada Region Agenda Regional Overview and Performance Regional Strategies Key Markets Conclusion 2 LA&C Regional
More informationQ Investor Kit January December 2014
Q4 2014 Investor Kit January December 2014 Highlights for Q4 Sales up for all product areas and operating profit from product areas up by 8% Scandinavian hoarding for snus prior to tax increase in January
More informationMANAGEMENT. MGMT 0021 THE MANAGEMENT PROCESS 3 cr. MGMT 0022 FINANCIAL ACCOUNTING 3 cr. MGMT 0023 MANAGERIAL ACCOUNTING 3 cr.
MANAGEMENT MGMT 0021 THE MANAGEMENT PROCESS 3 cr. An introduction designed to emphasize the basic principles, practices, and terminology essential to the understanding of contemporary business and its
More informationDuPont Nutrition & Health Craig Binetti, President
Craig Binetti, President Regulation G The attached charts include company information that does not conform to generally accepted accounting principles (GAAP). Management believes that an analysis of this
More informationQ Investor Kit JANUARY-JUNE 2014
Q2 2014 Investor Kit JANUARY-JUNE 2014 Swedish Match reporting segments Snus and moist snuff Snus (Scandinavia and US) Moist snuff (US) SMPM International Other tobacco products Cigars (US) Chewing tobacco
More informationQ Investor Kit JANUARY-MARCH 2014
Q1 2014 Investor Kit JANUARY-MARCH 2014 Swedish Match reporting segments Snus and moist snuff Snus (Scandinavia and US) Moist snuff (US) SMPM International Other tobacco products Cigars (US) Chewing tobacco
More informationTo be the partner of choice Straumann
To be the partner of choice Straumann Gilbert Achermann, CEO Helvea Swiss Equities Conference 11 January 2008, Bad Ragaz Table of contents 1. A snapshot of Straumann 2. Financials 3. Markets and opportunities
More informationUCB, with a strong year 2017, is reinforcing a solid foundation for investing in future growth
Brussels (Belgium), February 018 7:00 (CET) regulated information UCB Full Year Report 017: UCB, with a strong year 017, is reinforcing a solid foundation for investing in future growth Positive growth
More informationInvestor Presentation. Q April 26, 2018
Investor Presentation Q3 2018 April 26, 2018 Safe Harbor Statement Statements contained in this presentation that are not historical facts are forwardlooking statements as contemplated by the Private Securities
More informationDynamic Growth. Investora Gerhard Mahrle CFO COLTENE Holding AG. September 2018
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN. Investora 2018 Dynamic Growth Gerhard Mahrle CFO COLTENE Holding AG September 2018 COLTENE AN INTERNATIONALLY
More informationDistribution Partner Briefing: A Partnership for Profit. Welcome to Smartcool s information package for prospective channel partners.
Distribution Partner Briefing: A Partnership for Profit Welcome to Smartcool s information package for prospective channel partners. This publication is intended only as a general guide to assist you in
More informationImperial Brands Maximising Category Opportunities CAGNY February 2019
Imperial Brands Maximising Category Opportunities CAGNY 2019 21 February 2019 Disclaimer Certain statements in this announcement constitute or may constitute forward-looking statements. Any statement in
More informationView Report Details. Global Coronary Stent Market
View Report Details Global Coronary Stent Market ------------------------------------------------- 2013 View Report Details Executive Summary Coronary heart diseases are nowadays becoming more and more
More informationGlobal Invisible Braces Market: Trends, Opportunities and Forecasts ( )
Global Invisible Braces Market: Trends, Opportunities and Forecasts (2016-2021) By Types Clear Aligners, Ceramic, Lingual By Region Americas, Europe, Middle East, Africa, Asia-Pacific By Country- USA,
More informationFull Year Update FY2011 May 2011
Full Year Update FY2011 May 2011 1 Investment Highlights A leader in respiratory and OSA treatment devices Consistent growth strategy Estimated US$3.0+ billion and growing market opportunity High level
More informationMerrill Lynch Healthcare Conference New York
Merrill Lynch Healthcare Conference New York Matthew Emmens Chief Executive Officer February 3, 2004 A Strategic Review Today and Beyond Clear Strengths Highly successful business model Strong pipeline
More informationMerrill Lynch Conference Julian Heslop, CFO Sept 17 th 2010
Merrill Lynch Conference Julian Heslop, CFO Sept 17 th 2010 GSK s strategic priorities Grow a diversified global business Deliver more products of value Simplify the operating model Turnover and EPS progression
More informationInvestor Presentation
ASX:THC B u i l d i n g a M e d i c i n a l C a n n a b i s B u s i n e s s Investor Presentation November 2017 DISCLAIMER The material in this presentation (material) is not and does not constitute an
More informationQ Investor Kit JANUARY-JUNE 2013
Q2 2013 Investor Kit JANUARY-JUNE 2013 1 Swedish Match reporting segments Snus and snuff - Swedish snus (Scandinavia and US) - Moist snuff (US) - SMPM International Other tobacco products - Cigars (US)
More informationCorporate Presentation October New growth cycle and value innovation
Corporate Presentation October 2017 New growth cycle and value innovation Index 1 Dental benefits: an incipient sector in Brazil 2 Inside OdontoPrev 3 Strategic competitive advantages 4 Financial and Operational
More informationFor personal use only
ASX RELEASE (23 rd March 2018) AGM PowerPoint Presentaion In accordance with the requirements of Listing Rule 3.1 we submit the attached material being distributed at the Company s Annual General Meeting
More informationUroplasty, Inc. Investor Update Canaccord Genuity Conference December 6, 2011
Uroplasty, Inc. Investor Update Canaccord Genuity Conference December 6, 2011 Forward Looking Statement This presentation includes forward-looking statements, including financial projections, relating
More informationDELICA D:5 ACTIVE GEAR 0
DELICA D:5 ACTIVE GEAR 0 1 1. FY2017 1Q Results 2. FY2017 1Q Results by Region 3. FY2017 Forecast 4. Initiatives for the Future FY2017 1Q Results Summary (vs. FY2016 1Q) (Apr-Jun 2016) (Apr-Jun 2017) (billion
More informationA short introduction to DSM (2017) The global science-based company active in health, nutrition and materials
A short introduction to DSM (2017) The global science-based company active in health, nutrition and materials Mission Our purpose is to create brighter lives for people today and generations to come We
More informationGN Store Nord Goldman Sachs European Medtech and Healthcare Services Conference. CEO GN ReSound, Mike van der Wallen September 3, 2008
GN Store Nord Goldman Sachs European Medtech and Healthcare Services Conference CEO GN ReSound, Mike van der Wallen September 3, 2008 GN Store Nord A/S GN GN Store Store Nord Nord Listed Listed company
More informationFIRST QUARTER 2018 RESULTS 15 MAY 2018 LUCA BETTONTE, CEO
FIRST QUARTER 2018 RESULTS 15 MAY 2018 LUCA BETTONTE, CEO DISCLAIMER This document contains certain forward-looking information that is subject toa number of factors that may influence the accuracy of
More informationThe Dental Corporation Opportunity
The Dental Corporation Opportunity for Practice Principals. It s the perfect professional collaboration. You focus on dentistry, we look after the paperwork. In recognition of what you, the Practice Principal,
More informationSlide 1. Financial update and closing remarks. Jesper Brandgaard EVP and CFO. RAFAEL DE JESÚS FLORES, Mexico Rafael has haemophilia A
Slide 1 Financial update and closing remarks Jesper Brandgaard EVP and CFO RAFAEL DE JESÚS FLORES, Mexico Rafael has haemophilia A Slide 2 Forward-looking statements Novo Nordisk s reports filed with or
More informationGROWTH NOW! Franck Riboud
GROWTH NOW! Franck Riboud June 15 h, 2010 Disclaimer This document contains certain forward-looking statements concerning DANONE. Although DANONE believes its expectations are based on reasonable assumptions,
More informationDSM Capital Markets Day 2018
DSM Capital Markets Day 2018 Human Nutrition & Health Jeremy Xu President Human Nutrition & Health ROYAL DSM CAPITAL MARKETS DAY LONDON (UK) 20 JUNE 2018 Safe harbor statement This presentation may contain
More informationIncrease in revenues in line with full-year targets (+1.2%) Very strong growth of Oralair exc. USA (+26%) H revenues and results - 24 July 2014
Increase in revenues in line with full-year targets (+1.2%) Very strong growth of Oralair exc. USA (+26%) ( ) H1 2014 revenues and results - 24 July 2014 Forward-looking statement This presentation contains
More informationAn exciting combination in a high growth, high margin Nutrition category. Name of chairman
An exciting combination in a high growth, high margin Nutrition category 2 Vevey, December 14, 2006 Disclaimer This presentation contains forward looking statements which reflect Management s current views
More informationHarm de Wildt MD TNI
Harm de Wildt MD TNI Nutreco Capital Markets Day Derbyshire, UK 17 September 1 2013 Agenda 1 2 3 Market overview Animal Nutrition Europe Animal Nutrition strategic priorities Application Solution Centres
More informationWilliam Demant. Jefferies Healthcare Conf. Nov Søren B. Andersson, VP Investor Relations
William Demant Jefferies Healthcare Conf. Nov. 2017 Søren B. Andersson, VP Investor Relations Agenda General update Key take-aways from November Interim Statement Hearing Devices Outlook 2017 Q&A 2 General
More informationFor personal use only
FY2015 Half Year Results Presentation 6 months ended 30 September 2014 24 28 November 2014 1 First half result highlights H1 FY15 (6 months to 30 September 2014) PCP CC 1 Operating profit +8% +64% RAC
More informationImmunity for Life TM. Third Quarter CEO Lars Viksmoen CFO Finn Samuelsen. 31 October 2007
Immunity for Life TM Third Quarter 2007 CEO Lars Viksmoen CFO Finn Samuelsen 31 October 2007 Operational Highlights for Q3 2007 Clinical phase III study with SBG for treatment of diabetic ulcers; enrolment
More information